vs

Side-by-side financial comparison of Steris (STE) and UPBOUND GROUP, INC. (UPBD). Click either name above to swap in a different company.

Steris is the larger business by last-quarter revenue ($1.5B vs $1.2B, roughly 1.3× UPBOUND GROUP, INC.). Steris runs the higher net margin — 12.9% vs 1.7%, a 11.2% gap on every dollar of revenue. On growth, UPBOUND GROUP, INC. posted the faster year-over-year revenue change (10.9% vs 9.2%). Steris produced more free cash flow last quarter ($199.5M vs $24.0M). Over the past eight quarters, Steris's revenue compounded faster (15.8% CAGR vs 4.5%).

Steris plc is an American-Irish-based medical equipment company specializing in sterilization and surgical products for the US healthcare system. Steris is operationally headquartered in Mentor, Ohio, and has been legally registered in Dublin, Ireland, for tax purposes since 2018. Previously the company was registered in the United Kingdom from 2014 to 2018.

Upbound Group, Inc. is a leading US provider of flexible lease-to-own solutions for consumer goods. It offers furniture, consumer electronics, home appliances, and accessories, catering to customers seeking accessible payment alternatives to traditional retail financing.

STE vs UPBD — Head-to-Head

Bigger by revenue
STE
STE
1.3× larger
STE
$1.5B
$1.2B
UPBD
Growing faster (revenue YoY)
UPBD
UPBD
+1.7% gap
UPBD
10.9%
9.2%
STE
Higher net margin
STE
STE
11.2% more per $
STE
12.9%
1.7%
UPBD
More free cash flow
STE
STE
$175.5M more FCF
STE
$199.5M
$24.0M
UPBD
Faster 2-yr revenue CAGR
STE
STE
Annualised
STE
15.8%
4.5%
UPBD

Income Statement — Q3 FY2026 vs Q4 FY2025

Metric
STE
STE
UPBD
UPBD
Revenue
$1.5B
$1.2B
Net Profit
$192.9M
$19.7M
Gross Margin
43.8%
49.0%
Operating Margin
18.3%
4.8%
Net Margin
12.9%
1.7%
Revenue YoY
9.2%
10.9%
Net Profit YoY
11.2%
-36.3%
EPS (diluted)
$1.96
$0.35

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
STE
STE
UPBD
UPBD
Q4 25
$1.5B
$1.2B
Q3 25
$1.5B
$1.2B
Q2 25
$1.4B
$1.2B
Q1 25
$1.5B
$1.2B
Q4 24
$1.4B
$1.1B
Q3 24
$1.3B
$1.1B
Q2 24
$1.3B
$1.1B
Q1 24
$1.1B
$1.1B
Net Profit
STE
STE
UPBD
UPBD
Q4 25
$192.9M
$19.7M
Q3 25
$191.9M
$13.2M
Q2 25
$177.4M
$15.5M
Q1 25
$145.7M
$24.8M
Q4 24
$173.5M
$31.0M
Q3 24
$150.0M
$30.9M
Q2 24
$145.4M
$33.9M
Q1 24
$-1.4M
$27.7M
Gross Margin
STE
STE
UPBD
UPBD
Q4 25
43.8%
49.0%
Q3 25
44.2%
48.3%
Q2 25
45.1%
49.4%
Q1 25
43.3%
46.8%
Q4 24
44.5%
47.1%
Q3 24
43.6%
47.8%
Q2 24
44.7%
49.4%
Q1 24
40.2%
48.3%
Operating Margin
STE
STE
UPBD
UPBD
Q4 25
18.3%
4.8%
Q3 25
18.2%
4.5%
Q2 25
17.7%
4.4%
Q1 25
14.6%
5.3%
Q4 24
17.9%
7.3%
Q3 24
16.5%
6.6%
Q2 24
14.5%
7.5%
Q1 24
22.0%
5.6%
Net Margin
STE
STE
UPBD
UPBD
Q4 25
12.9%
1.7%
Q3 25
13.1%
1.1%
Q2 25
12.8%
1.3%
Q1 25
9.8%
2.1%
Q4 24
12.7%
2.9%
Q3 24
11.3%
2.9%
Q2 24
11.4%
3.2%
Q1 24
-0.1%
2.5%
EPS (diluted)
STE
STE
UPBD
UPBD
Q4 25
$1.96
$0.35
Q3 25
$1.94
$0.22
Q2 25
$1.79
$0.26
Q1 25
$1.48
$0.42
Q4 24
$1.75
$0.55
Q3 24
$1.51
$0.55
Q2 24
$1.46
$0.61
Q1 24
$-0.02
$0.50

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
STE
STE
UPBD
UPBD
Cash + ST InvestmentsLiquidity on hand
$423.7M
$120.5M
Total DebtLower is stronger
$1.9B
Stockholders' EquityBook value
$7.2B
$695.7M
Total Assets
$10.6B
$3.3B
Debt / EquityLower = less leverage
0.27×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
STE
STE
UPBD
UPBD
Q4 25
$423.7M
$120.5M
Q3 25
$319.2M
$107.0M
Q2 25
$279.7M
$106.8M
Q1 25
$171.7M
$107.3M
Q4 24
$155.2M
$60.9M
Q3 24
$172.2M
$85.1M
Q2 24
$198.3M
$82.5M
Q1 24
$207.0M
$84.8M
Total Debt
STE
STE
UPBD
UPBD
Q4 25
$1.9B
Q3 25
$1.9B
Q2 25
$1.9B
Q1 25
$1.9B
Q4 24
$2.0B
Q3 24
$2.2B
Q2 24
$2.2B
Q1 24
$3.1B
Stockholders' Equity
STE
STE
UPBD
UPBD
Q4 25
$7.2B
$695.7M
Q3 25
$7.0B
$687.3M
Q2 25
$7.0B
$685.5M
Q1 25
$6.6B
$679.2M
Q4 24
$6.4B
$629.0M
Q3 24
$6.6B
$611.8M
Q2 24
$6.4B
$596.3M
Q1 24
$6.3B
$578.3M
Total Assets
STE
STE
UPBD
UPBD
Q4 25
$10.6B
$3.3B
Q3 25
$10.4B
$3.2B
Q2 25
$10.4B
$3.1B
Q1 25
$10.1B
$3.0B
Q4 24
$10.0B
$2.6B
Q3 24
$10.2B
$2.6B
Q2 24
$10.1B
$2.6B
Q1 24
$11.1B
$2.6B
Debt / Equity
STE
STE
UPBD
UPBD
Q4 25
0.27×
Q3 25
0.27×
Q2 25
0.27×
Q1 25
0.29×
Q4 24
0.32×
Q3 24
0.33×
Q2 24
0.35×
Q1 24
0.50×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
STE
STE
UPBD
UPBD
Operating Cash FlowLast quarter
$298.2M
$41.6M
Free Cash FlowOCF − Capex
$199.5M
$24.0M
FCF MarginFCF / Revenue
13.3%
2.0%
Capex IntensityCapex / Revenue
6.6%
1.5%
Cash ConversionOCF / Net Profit
1.55×
2.11×
TTM Free Cash FlowTrailing 4 quarters
$917.1M
$238.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
STE
STE
UPBD
UPBD
Q4 25
$298.2M
$41.6M
Q3 25
$287.8M
$118.4M
Q2 25
$420.0M
$7.8M
Q1 25
$260.8M
$137.7M
Q4 24
$332.8M
$-61.9M
Q3 24
$250.7M
$106.2M
Q2 24
$303.7M
$15.0M
Q1 24
$254.8M
$45.4M
Free Cash Flow
STE
STE
UPBD
UPBD
Q4 25
$199.5M
$24.0M
Q3 25
$201.3M
$97.9M
Q2 25
$326.4M
$-10.4M
Q1 25
$189.9M
$127.2M
Q4 24
$243.6M
$-74.0M
Q3 24
$148.8M
$88.3M
Q2 24
$195.7M
$613.0K
Q1 24
$163.3M
$33.6M
FCF Margin
STE
STE
UPBD
UPBD
Q4 25
13.3%
2.0%
Q3 25
13.8%
8.4%
Q2 25
23.5%
-0.9%
Q1 25
12.8%
10.8%
Q4 24
17.8%
-6.9%
Q3 24
11.2%
8.3%
Q2 24
15.3%
0.1%
Q1 24
14.6%
3.1%
Capex Intensity
STE
STE
UPBD
UPBD
Q4 25
6.6%
1.5%
Q3 25
5.9%
1.8%
Q2 25
6.7%
1.6%
Q1 25
4.8%
0.9%
Q4 24
6.5%
1.1%
Q3 24
7.7%
1.7%
Q2 24
8.4%
1.3%
Q1 24
8.2%
1.1%
Cash Conversion
STE
STE
UPBD
UPBD
Q4 25
1.55×
2.11×
Q3 25
1.50×
8.96×
Q2 25
2.37×
0.50×
Q1 25
1.79×
5.56×
Q4 24
1.92×
-2.00×
Q3 24
1.67×
3.44×
Q2 24
2.09×
0.44×
Q1 24
1.64×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

STE
STE

Servicerevenues$404.7M27%
Consumablerevenues$387.1M26%
Applied Sterilization Technologies$286.6M19%
Capitalequipmentrevenues$272.1M18%
Life Science$145.8M10%

UPBD
UPBD

Segment breakdown not available.

Related Comparisons